BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 7, 2020
View Archived Issues
TXNIP inhibition nixes T2D
Read More
Supportive preclinical reported for PTX-COVID19-B vaccine candidate
Read More
First-in-human data presented for NTRX-07
Read More
Daiichi Sankyo patents new SIRT6 activators
Read More
Merck & Co. synthesizes HDAC inhibitors
Read More
Chinese researchers identify LPAR1 antagonists
Read More
Innate Tumor Immunity discloses NLRP3 agonists
Read More
New adenosine A2A receptor antagonists discovered by Nuvation Bio
Read More
Boehringer Ingelheim initiates first-in-human study of BI-764532
Read More
Structure-guided analysis unveils the mechanism of action of a dengue virus 2-specific inhibitor
Read More
SASS6 is involved in the proliferation of esophageal cancer and may be a novel therapeutic target
Read More
AstraZeneca is enrolling participants in phase I study of MEDI-8367
Read More
First patient enrolled in phase IIb/III study of ifenprodil for treatment of COVID-19
Read More
Six-month follow-up data announced from phase I study of INXN-4001
Read More
Anti-podocalyxin [225Ac]PODO-447 shows promise as immunotherapeutic for treating solid tumors
Read More
Dicerna provides data updates from clinical and preclinical developments
Read More
Topline data presented from phase III CARE-PWS study of LV-101
Read More
Phase II/III study of opaganib in patients with COVID-19 receives approval in Mexico
Read More
FDA clears IND for phase II study of TNX-102 SL
Read More
First patient dosed in a phase Ib/II study FGF-401 plus pembrolizumab
Read More
Study links mitochondrial DNA to abscopal response
Read More
Roche gives update on phase III IMpassion131 study of Tecentriq
Read More
GlycoNex initiates phase I study of GNX-102
Read More
First-in-human study of DC immunotherapy in patients with pancreatic adenocarcinoma
Read More
EC approves Xolair as treatment of severe chronic rhinosinusitis with nasal polyps
Read More